A panel of the European medicines regulator has recommended approving an eco-friendly version of AstraZeneca's inhaler for the treatment of a chronic lung condition, th ...

AstraZeneca (AZN) said on Friday that it received positive results from two late-stage trials for its triple-combination therapy Breztri Aerosphere in patients with uncontrolled asthma.

According to pricing data from the lawmakers, AstraZeneca’s Breztri Aerosphere inhaler costs $645 in the U.S. but just $49 in the U.K. “We remain dedicated to addressing the need for ...

AstraZeneca (AZN) has initiated a Phase 3 study to evaluate the use of Breztri Aerosphere on severe cardiopulmonary outcomes, including death, in people with COPD. Read more here.

BREZTRI AEROSPHERE is approved to treat COPD in more than 50 countries worldwide including the US, EU, China and Japan, and is currently being studied in Phase III trials for asthma. About SYMBICORT® ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced the initiation of a Phase III trial to investigate the potential effect of triple-combination inhaled therapy BREZTRI AEROSPHERE ...

According to pricing data from the lawmakers, AstraZeneca’s Breztri Aerosphere inhaler costs $645 in the U.S. but just $49 in the U.K.

According to pricing data from the lawmakers, AstraZeneca’s Breztri Aerosphere inhaler costs $645 in the U.S. but just $49 in the U.K.

According to pricing data from the lawmakers, AstraZeneca’s Breztri Aerosphere inhaler costs $645 in the U.S. but just $49 in the U.K.